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Abstract Annexins (ANXs) are a family of proteins with
calcium-dependent phospholipid binding properties. Although
inhibition of phospholipase A2 (PLA2) by ANX-I has been
reported, the mechanism is still controversial. Previously we
proposed a ‘specific interaction’ model for the mechanism of
cytosolic PLA2 (cPLA2) inhibition by ANX-I [Kim et al., FEBS
Lett. 343 (1994) 251^255]. Here we have studied the cPLA2
inhibition mechanism using ANX-I, N-terminally deleted ANX-I
(vANX-I), ANX-II, ANX-II2P112, ANX-III, and ANX-V.
Under the conditions for the specific interaction model, ANX-I,
vANX-I, and ANX-II2P112 inhibited cPLA2, whereas inhibition
by ANX-II and ANX-III was negligible. Inhibition by ANX-V
was much smaller than that by ANX-I. The protein^protein
interactions between cPLA2 and ANX-I, vANX-I, and ANX-
II2P112 were verified by immunoprecipitation. We can therefore
conclude that inhibition of cPLA2 by specific interaction is not a
general function of all ANXs, and is rather a specific function of
ANX-I. The results are consistent with the specific interaction
model. ß 2001 Federation of European Biochemical Societies.
Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Annexins (ANXs) (also called lipocortins) are a family of
intracellular proteins that bind phospholipids and membranes
in a Ca2-dependent manner [1]. Several members of the
ANX family have been implicated in the regulation of cellular
processes including membrane fusion, in£ammation, prolifer-
ation, and di¡erentiation [2^5]. However, despite many func-
tional possibilities, well-characterized biological functions or
relationships between structure and function have not been
determined for any of the ANXs.
The structure of ANXs consists of an N-terminal tail and a
C-terminal core domain. The core domain consists of four or
eight repeats of a highly homologous 70 amino acid sequence,
which is known to be a common primary structure for the
binding of Ca2, phospholipids, and ATP [1,6,7]. The N-ter-
minal domains of the ANXs have great diversity in both
length and sequence. Since these domains contain the sites
for phosphorylation and selective proteolytic cleavage, they
are considered to be the regulatory region of each protein
and seem to be important for the speci¢c cellular functions
of each ANX [8].
ANX-I has been shown to inhibit phospholipase A2
(PLA2); however, the mechanism of the inhibition is still con-
troversial [9]. PLA2 represents a growing family of enzymes
with a common function of catalyzing the release of fatty acid
from the sn-2 position of membrane phospholipids, thereby
leading to production of lipid metabolites including arachi-
donic acid, leukotrienes, and lysophospholipids [10,11]. There
are at least three types of PLA2s, secretary PLA2 (sPLA2),
cytosolic PLA2 (cPLA2), and Ca2-independent PLA2
(iPLA2) [10]. Detailed enzymatic studies have shown that
ANX-I inhibits cPLA2, a 100 kDa protein of submicromolar
Ca2 requirement, by ‘speci¢c interaction’ [12]. Other studies
using sPLA2, a 14 kDa protein of millimolar Ca2 require-
ment, have demonstrated that the inhibition is due to the
ability of ANX-I to bind to the substrate, which results in
substrate depletion and apparent inhibition [13,14]. Increasing
reports suggest that cPLA2 is a key enzyme responsible for
signal transduction in in£ammation, cytotoxicity and mito-
genesis [10,11]. ANX-I suppresses cPLA2 activity not only
in the in vitro system but also in cultured cells [15,16]. Thus
ANX-I may function as an endogenous negative regulator of
cPLA2.
Since ANXs share most of their functions, probably
through the homology in the core domain, it is important
to know whether the inhibition of cPLA2 is a general function
of all ANXs or a speci¢c function of ANX-I. If the substrate
depletion mechanism is correct, all ANXs should display sim-
ilar inhibition patterns towards di¡erent types of PLA2s. Also
it is important to know whether the inhibitory activity is in
the N-terminal or in the core domain of ANX-I. Herein we
have studied the inhibition of cPLA2 using various forms of
ANXs, including ANX-I and N-terminally deleted ANX-I
(vANX-I), in which amino acids 1^32 were deleted. E¡ects
of ANX-II, ANX-II2P112 tetramer, ANX-III, and ANX-V on
the activity of cPLA2 were also investigated.
2. Materials and methods
2.1. Chemicals and reagents
1-Stearoyl-2-[1-14C]arachidonyl-sn-glycero-3-phosphocholine (2-AA-
PC) (56.0 mCi/mmol) and 1-acyl-2-[1-14C]arachidonyl-sn-glycero-3-
phosphoethanolamine (2-AA-PE) (57.0 mCi/mmol) were purchased
from Amersham (Buckinghamshire, UK) and used as substrates. Un-
labeled 2-AA-PC and 2-AA-PE were purchased from Sigma (St.
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Louis, MO, USA). Scintillation £uid (Aquasol-2) was from NEN
Probe (Eugene, OR, USA). All other reagents were of analytical re-
agent grade or better.
Rabbit antiserum was raised against human ANX-I produced in
Escherichia coli. Mouse anti-ANX-I antibody was purchased from
Transduction Laboratories (Lexington, KY, USA). Mouse anti-
ANX-II monoclonal antibody was purchased from Zymed (USA).
Rabbit anti-ANX-V antibody and mouse anti-cPLA2 antibody were
from Santa Cruz Biotechnology Inc. (USA). Anti-rabbit HRP (horse-
radish peroxidase) and anti-mouse HRP were purchased from Caltag
Laboratories (USA).
2.2. Preparation of ANXs
Recombinant ANX-I and vANX-I (in which amino acids 1^32
were deleted) were produced in E. coli and puri¢ed as described pre-
viously [17]. ANX-II and ANX-II2P112 were the kind gifts of Dr.
Waisman of University of Calgary, Canada [18]. ANX-III was pro-
duced in E. coli as a GST fusion protein using the expression plasmid
which was kindly provided by Dr. Russo-Marie of INSERM, Paris,
France [19]. ANX-III was puri¢ed after cutting o¡ the GST tail.
ANX-V was purchased from Sigma (St. Louis, MO, USA).
2.3. Preparation of cPLA2 and sPLA2
Bee venom sPLA2 was purchased from Sigma (St. Louis, MO,
USA). A 100 kDa cPLA2 was partially puri¢ed from porcine spleen
essentially according to the methods described previously [20]. Since
puri¢cation of cPLA2 from porcine spleen is laborious and time con-
suming, we cloned the cPLA2 cDNA in a baculovirus vector pFast
Bac HT (Gibco-BRL, USA) and produced cPLA2 in sf9 cells (details
will be published elsewhere). Cells from 50 ml culture were lysed in
1 ml of bu¡er (20 mM Tris/HCl pH 7.4, 10% glycerol, 1% NP-40,
0.1% BSA, 0.1 mM PMSF, Complete1EDTA free tablet, 0.1 M
Ca2) and used as the source of sf9-cPLA2.
2.4. Standard assay for PLA2 activity
PLA2 activity was assayed using sonicated liposomes prepared as
described previously [12,19]. A stock solution of the substrate was
prepared as follows: 10^20 nmol of the substrate was dried under
nitrogen, then suspended in 0.5^1.0 ml of distilled water by sonication
(10 sU3) in a bath-type sonicator (Ultrasonik 300, NEY). The stan-
dard reaction mixture (200 Wl) for PLA2 assay contained 0.33 nmol
(1.65 WM) of radioactive substrate (approximately 39 000 cpm), 200 Wg
of fatty acid-free bovine serum albumin (BSA) and 10 ng of PLA2 in
75 mM Tris/HCl (pH 7.5). The reaction was started by adding the
enzyme to the reaction mixture and was incubated at 37‡C for 1 h.
Non-esteri¢ed fatty acid was extracted as follows. First, 0.55 ml of
water was added and the sample was vortex-mixed and centrifuged at
5600Ug for 5 min. Then 0.75 ml of the upper phase was transferred
to a new tube, to which 100 mg of silica gel and 0.75 ml of n-heptane
were added. The samples were vortex-mixed and centrifuged again for
5 min. The supernatant was dried with a Speed Vac freeze drier and
the lipid was resuspended in chloroform/methanol (1:1, v/v) which
contained unlabeled arachidonic acid (1 Wg/Wl) in methanol. Phospho-
lipid and neutral lipid were separated by migration on layers of silica
gel 60 F254 (Merck, Darmstadt, Germany) plate in petroleum ether/
ethyl ether/acetic acid (80:20:1, v/v/v). After drying, the plates were
subjected to iodine vapor and lipids were identi¢ed by their co-migra-
tion with unlabeled arachidonic acids. Products were quanti¢ed by
scraping their corresponding spots into counting vials containing
2 ml of Aquasol-2. Radioactivity was determined using a Packard
Tri-Carb scintillation spectrophotometer. For experiments in which
the substrate concentration dependence was determined, unlabeled
phospholipid was added to labeled phospholipid to give a designated
¢nal concentration. For accurate control of Ca2 concentration, a
CaCl2/EGTA bu¡ering system was used [21]. In all analyses, samples
were tested in triplicates and were adjusted for non-speci¢c release by
subtracting a control value in which preparation of the enzyme was
omitted. For inhibition assays, 20^100 nM of ANXs were added to
the reaction mixture.
2.5. Immunoprecipitation of cPLA2bANX complexes with
ANX antibodies
The lysate of the sf9 cells over-expressing cPLA2 was used in this
experiment. 50 Wl of the sf9-cPLA2 lysate was incubated at 4‡C for 2 h
with or without 2 Wg each of ANX and 200 Wg of BSA in 200 Wl of
bu¡er (75 mM Tris/HCl pH 7.4, 0.1 WM Ca2). Anti-ANX antibody
corresponding to each ANX was added and the samples were incu-
bated further for 1 h, then immune complexes were precipitated with
Protein-A agarose (Santa Cruz Biotechnology Inc, CA, USA). The
cPLA2 activity in the precipitate or in the supernatant was determined
in the standard bu¡er containing 5 mM CaCl2.
The cPLA2 in the pellet was also analyzed by Western blot. The
pellet was boiled in the gel loading bu¡er and proteins were separated
by 10% SDS^PAGE, and then transferred to a nitrocellulose mem-
brane (Schleicher and Schuel, Keene, NH, USA). The membrane was
probed with monoclonal antibody to cPLA2 and visualized using the
ECL system (Amersham, Buckinghamshire, UK).
2.6. Expression of data
All determinations were carried out in triplicate, and experiments
were repeated at least three times. All data are shown as mean þ
S.E.M. E¡ects of ANXs were presented by the percentage of cPLA2
activity compared to the control value.
3. Results
3.1. E¡ect of calcium on the activity of PLA2s from di¡erent
sources
In the previous experiments of cPLA2 inhibition by ANX-I,
cPLA2 from porcine spleen was used [12]. To characterize the
recombinant cPLA2 from sf9 cells, the enzymatic activity was
measured under various Ca2 ion concentrations. The sf9-
cPLA2 was active under Ca2 concentrations as low as 0.1
WM and showed nearly identical activity with porcine spleen
cPLA2 under all Ca2 concentrations (Fig. 1). On the other
hand at least 0.1 mM Ca2 was necessary for the sPLA2
activity. Therefore sf9-cPLA2 was used in all other experi-
ments.
3.2. Calcium dependence of the cPLA2 inhibition by ANXs
In order to investigate the mechanism of cPLA2 inhibition
by ANXs in detail, assays were carried out under various
concentrations of ANXs and Ca2 ion. ANX-I, vANX-I,
ANX-II, ANX-II2P112, ANX-III, and ANX-V were used. In-
hibition of cPLA2 by ANXs was determined using 2-AA-PC
as a substrate at 0.1, 1, 10, 100 WM, and 1 mM Ca2 ion
concentrations. The substrate concentration was 1.65 WM,
Fig. 1. Calcium dependence of the PLA2 activity. PLA2s from dif-
ferent sources were used. PLA2 activity was determined using
1-stearoyl-2-[1-14C]-sn-glycero-phosphocholine (2-AA-PC, approxi-
mately 39 000 cpm) as a substrate in 75 mM Tris^HCl (pH 7.5) in
the presence of various concentrations of free Ca2 as described in
Section 2. b, Recombinant cPLA2 produced in sf9 cells harboring
the recombinant baculovirus (sf9-cPLA2). R, Partially puri¢ed por-
cine spleen cPLA2. F, Bee venom secretory PLA2 (sPLA2) pur-
chased from Sigma. Data represent mean þ S.E.M. of triplicate ex-
periments and the ¢gure is a representative of three independent
experiments.
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which was a large excess over the enzyme (0.5 nM) and in-
hibitor (20^100 nM) concentrations. Fig. 2 shows the percent-
age of the remaining 2-AA-PC hydrolyzing activity in pres-
ence of ANXs. In presence of ANX-I the PLA2 activity
decreased, suggesting inhibition of the enzymatic activity
(Fig. 2A). The inhibition reached a plateau at 20 nM ANX-
I, the lowest concentration used in this experiment. Percent
remaining activity was smallest, and therefore, percent inhibi-
tion was largest at 0.1 WM or 1 WM Ca2 concentration. It
decreased with increasing Ca2 concentration, and became
negligible at 1 mM Ca2 concentration. These results are con-
sistent with the following interpretation. Binding of ANX-I to
the substrate is Ca2 dependent. At Ca2 concentration of 0.1
WM or 1 WM, substrate binding by ANX-I is minimal, and
therefore, ANX-I is available for PLA2 inhibition. Substrate
binding by ANX-I increases with increasing calcium concen-
tration, which results in the reduction of free ANX-I for
cPLA2 inhibition. At 1 mM Ca2 concentration, ANX-I is
depleted by binding to the substrate and unavailable for
cPLA2 inhibition.
To determine the importance of the N-terminal sequence
for the inhibitory activity, vANX-I was used as an inhibitor.
As shown in Fig. 2B, the pattern of the inhibition was similar
to that of ANX-I. Even though the inhibition by vANX-I was
slightly less than that of ANX-I, it was within the day to day
variation range. Therefore the N-terminal sequence is not
likely to be very important for the inhibition. Inhibition by
ANX-II was very small compared to that of ANX-I. Interest-
ingly ANX-II2P112 showed a marked inhibition, whereas
ANX-III had virtually no e¡ect on cPLA2 activity. Inhibitory
e¡ect of ANX-V on the cPLA2 activity was much smaller
compared to that of ANX-I. At 1 WM calcium where the
inhibition was the maximum, the inhibition by ANX-I
reached to a near maximum value (55%) at 20 nM (Fig.
2A), whereas the inhibition by ANX-V reached to 40% at
100 nM (Fig. 2F). To give 40% inhibition, 10 nM of ANX-I
was needed (data not shown).
Fig. 3 shows a replotting of data in Fig. 2. The remaining
cPLA2 activity in the presence of ANXs was plotted against
the logarithmic value of the Ca2 concentration. In all cases
the plot was essentially linear except for the values at 0.1 WM
calcium. In case of ANX-I, vANX-I, and ANX-II2P112, in-
hibition at 0.1 WM calcium and at 1 WM calcium was very
similar. Inhibition by ANX-V at 1 WM was larger than that at
0.1 WM calcium; however, experiments at 0.1 WM calcium
were prone to more error due to the lower value of the
cPLA2 assay and the di¡erence was insigni¢cant (Fig. 1).
The slope for ANX-I is the largest and that for ANX-II2P112
is the smallest. Therefore the inhibition by ANX-I mostly
depends on the Ca2 concentration and ANX-II2P112 is the
least a¡ected by this.
3.3. Substrate concentration dependence of the
cPLA2 inhibition by ANXs
To rule out the possibility that the cPLA2 inhibition by
ANXs is due to substrate depletion, the substrate concentra-
tion was varied from 1.65 WM to 33 WM while holding other
Fig. 2. Inhibition of cPLA2 by ANXs. Inhibition of cPLA2 activity
by various ANXs was determined using 2-AA-PC as a substrate
under various Ca2 concentrations. The sf9-cPLA2 was used in this
experiment. Concentrations of cPLA2 and the substrate were ap-
proximately 0.5 nM (10 ng/200 Wl) and 1.65 WM, respectively. Con-
centrations of ANXs were varied from 20 nM to 100 nM. cPLA2
activity with or without ANXs was determined and the percentage
of the activity in the presence of ANXs was calculated. P, 0.1 WM
Ca2 ; b, 1 WM Ca2 ; F, 10 WM Ca2 ; R, 100 WM Ca2 ; 7, 1 mM
Ca2. Data represent mean þ S.E.M. of triplicate experiments and
the ¢gure is a representative of three independent experiments.
Fig. 3. Ca2 concentration dependence of the cPLA2 inhibition by
ANXs. Data in Fig. 2 are replotted against Ca2 concentration.
b, 20 nM; F, 60 nM; R, 100 nM of ANXs. Other details were as
in Fig. 2.
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components constant. Both 2-AA-PC and 2-AA-PE were used
as substrates. As shown in Fig. 4, inhibition of cPLA2 by
ANX-I, vANX-I, and ANX-II2P112 was essentially independ-
ent of substrate concentration. On the other hand ANX-V
showed some inhibitory activity only at the lowest substrate
concentration (1.65 WM) and virtually had no activity at high-
er substrate concentrations. If the mechanism was substrate
depletion, increasing the substrate concentration would abol-
ish the inhibition [13]. Therefore the results in Fig. 4 demon-
strate that the mechanism of cPLA2 inhibition by ANX-I is
speci¢c interaction and not substrate depletion. It is likely that
the inhibitory e¡ect of ANX-V is mainly due to substrate
depletion.
3.4. Immunoprecipitation of cPLA2bANX complex by
anti-ANX antibody
To demonstrate that cPLA2 inhibition by ANX-I, vANX-I,
and ANX-II2P112 is due to direct interaction between cPLA2
and ANXs, anti-ANX antibodies were used to investigate the
stability and co-precipitability of cPLA2 and ANX complexes.
Since inhibition by speci¢c interaction was observed under
intracellular calcium concentration 0.1 WM (Figs. 2, 3), the
immunoprecipitation was performed under 0.1 WM calcium
concentration. The binding mixture contained cPLA2, each
ANX, and the speci¢c antibody to each ANX; for example
in the mixture for ANX-I, anti-ANX-I antibody was included.
The results are shown in Table 1. In case of ANX-I or
vANX-I, the cPLA2 activity was mostly in the pellet, suggest-
ing that the cPLA2bANX-I or cPLA2bvANX-I complex was
precipitated with the anti-ANX-I antibody. The cPLA2bANX-
II2P112 complex was also precipitated with anti-ANX-II anti-
body. On the other hand when precipitated with anti-ANX-V
antibody cPLA2 activity was mostly in the supernatant indi-
cating the lack of cPLA2bANX-V complexes in the pellet. To
further verify the precipitation of cPLA2bANX complexes by
ANX antibodies, Western blot analysis was performed. The
pellet obtained as in Table 1 was dissolved in the gel loading
bu¡er, separated on a 10% SDS^PAGE gel, and analyzed by
Western blot using anti-cPLA2 antibody. As shown in Fig. 5,
cPLA2 was present in the precipitates of ANX-I, vANX-I,
and ANX-II2P112. In case of ANX-V, the interaction with
cPLA2 was very weak. The result in Fig. 5 is consistent
with the data in Table 1 as well as the cPLA2 inhibition by
ANXs at 0.1 WM calcium concentration as shown in Figs. 2
and 3.
4. Discussion
The mechanism by which ANX-I inhibits cPLA2 activity is
still a controversial issue. In this contribution we tried to
address this issue by determining the e¡ects of ANX-I as
well as other ANXs on cPLA2 activity. We have demon-
Fig. 4. Inhibition of cPLA2 by ANXs under higher substrate con-
centrations. The concentrations of Ca2 and ANXs were 1 WM and
20 nM, respectively. The substrate concentrations were varied from
1.65 WM to 33.0 WM. b, 2-AA-PC; F, 2-AA-PE. Other details were
as in Fig. 2.
Table 1
cPLA2 activity in the supernatant or pellet after immunoprecipitation with anti-ANX antibodies
Immunoprecipitation mixture cPLA2 activity (%)
Pellet Supernatant
cPLA2+BSA+anti-PLA2 antibody 98.2 þ 2.5 1.2 þ 0.5
cPLA2+BSA+anti-ANX-I antibody 1.2 þ 0.1 99.1 þ 4.1
cPLA2+ANX-I+anti-ANX-I antibody 75.1 þ 3.9 20.4 þ 3.1
cPLA2+vANX-I+anti-ANX-I antibody 70.6 þ 8.3 23.5 þ 2.3
cPLA2+ANX-II2P112+anti-ANX-II antibody 51.5 þ 3.7 26.1 þ 7.9
cPLA2+ANX-V+anti-ANX-V antibody 11.7 þ 3.5 85.9 þ 7.1
The immunoprecipitation mixture contained sf9-cPLA2 cell lysate, each ANX, and speci¢c antibody to each ANX. cPLA2 activity in the super-
natant or pellet after immunoprecipitation was determined. Data represent mean þ S.E.M. of triplicate experiments.
Fig. 5. Immunoprecipitation of the cPLA2bANX complex with
ANX antibodies. The sf9-cPLA2 cells were grown and the cell ly-
sate was used in this experiment as described in Section 2. The incu-
bation mixture contained 50 Wl of sf9-cPLA2 lysate, 200 Wg of BSA,
2 Wg of each ANX, and speci¢c antibody to each ANX in 200 Wl of
bu¡er (75 mM Tris^HCl pH 7.4, 0.1 WM Ca2). The cPLA2bANX
complexes were immunoprecipitated with Protein-A agarose and an-
alyzed by Western blot as described in Section 2. The blot was
probed with anti-cPLA2 antibody, and visualized using HRP-conju-
gated anti-rabbit antibody and the ECL system (Amersham, UK).
Controls: Cont, cPLA2 only; Rabbit IgG and Mouse IgG, preim-
mune.
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strated that (1) cPLA2 is speci¢cally inhibited by ANX-I
under the conditions of speci¢c interaction, (2) deletion of
the N-terminal tail has little e¡ect on the inhibitory activity,
(3) while ANX-II does not inhibit cPLA2, ANX-II2P112 does,
(4) ANX-III does not inhibit cPLA2, and (5) ANX-V has
much less inhibitory activity. In addition, immunoprecipita-
tion studies have revealed that cPLA2 forms complexes with
ANX-I, vANX-I, and ANX-II2P112, but not with ANX-II
and ANX-III, and much less e⁄ciently with ANX-V, which
are in good agreement with the enzymatic studies.
Inhibition of cPLA2 by various members of the ANX fam-
ily has been reported. However, most of the data were from
the experiments performed under the conditions where the
substrate depletion mechanism dominates [22^24]. Even
though there have been no detailed enzymatic studies on the
mechanism of cPLA2 inhibition by ANXs other than ANX-I,
most articles in the literature describe the mechanism as ‘sub-
strate depletion’. There is only one report, in fact by us, that
concludes the inhibition mechanism is by ‘speci¢c interaction’
[12]. If the mechanism is ‘substrate depletion’, all ANXs
should display similar inhibition patterns because this mech-
anism is due to the ability of ANXs to bind to phospholipids.
Fig. 2 clearly demonstrates that this is not the case. Therefore
the di¡erential e¡ects of ANXs on the cPLA2 inhibition pro-
vide more supportive evidence for the ‘speci¢c interaction’
model. The inhibitory e¡ect of ANX-I is independent of the
substrate concentration, whereas that of ANX-V was abol-
ished with increasing substrate concentration (Fig. 4D). This
result provides additional support that the inhibition mecha-
nism of ANX-I, but not of ANX-V, is speci¢c interaction.
Since the N-terminal region is speci¢c to each ANX, we
asked whether this region is important for the cPLA2 inhibi-
tion by ANX-I. To our surprise, deleting the N-terminal re-
gion had little e¡ect on the cPLA2 inhibitory activity of
ANX-I. This indicates that even though the core domain se-
quences are highly conserved, there are enough di¡erences to
di¡erentiate the cPLA2 binding properties. This phenomenon
is supported by the fact that anti-ANX-I antibody derived
from human ANX-I speci¢cally recognizes all ANX-I across
the species from mold to human, while it does not recognize
any other types of ANXs from any source including human
cells (unpublished observation). In view of the speci¢city of
the N-terminal for each ANX, the N-terminal of ANX-I
would be related to other speci¢c functions of ANX-I, such
as mediation of anti-in£ammatory function of glucocorticoids
[25^27], and translocation from the cytosol to the nucleus by
epidermal growth factor or stress signals [5,28^30].
As shown in Figs. 2, 5, and Table 1, ANX-II does not
inhibit cPLA2, while ANX-II2P112 does. This result is consis-
tent with the previously reported observation by Wu and
others [31] that P11 but not ANX-II binds and inhibits
cPLA2. Two immediate questions are (1) whether ANX-I
and P11 have any homology, and (2) whether they share the
same binding site on cPLA2. Comparison of ANX-I and P11
sequences shows no signi¢cant homology. Results from the
preliminary experiments suggest that the binding sites are dif-
ferent (unpublished observation). Another point to be noted is
that the Ca2 concentration dependence of the cPLA2 inhibi-
tion by ANX-II2P112 is less than that by ANX-I or vANX-I
(Fig. 3). This seems to be due to the fact that there is no Ca2
binding site on P11, the e¡ector subunit of cPLA2 inhibition
[31]. This may also be the reason for the results that the
cPLA2 activity in the supernatant and in the pellet does not
add up to near 100%, representing the inhibition of cPLA2
under 5 mM Ca2 concentration used in the assay (Table 1).
Whether the cPLA2 inhibition by ANX-I occurs in vivo is
still an open question. Inhibition of cPLA2 under physiolog-
ical calcium concentrations suggests that the inhibition may
occur in cells and is related to the regulation of cPLA2 activ-
ity. However since the inhibition at 0.1 WM calcium (resting
state) and at 1 WM calcium (activated state) is similar, it is
unlikely that this is a major mechanism for cPLA2 regulation
in cells. It may rather be related to other mechanisms of
cPLA2 regulation such as phosphorylation. In conclusion,
the mechanism of cPLA2 inhibition by ANX-I is consistent
with the ‘speci¢c interaction’ model and the patterns of
cPLA2 inhibition by ANXs support this mechanism. The
cPLA2 inhibition is a speci¢c function of ANX-I and is not
a general function of all ANXs. The N-terminal region may
not be very important for cPLA2 inhibition. The results pre-
sented here are potentially important since ANX-I speci¢cally
inhibited cPLA2 near intracellular Ca2 concentration. ANX-
I may regulate several biological processes through regulation
of cPLA2 activity.
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